Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory patent allowance

Silo Pharma SPC-15 US Patent Allowance

Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
5
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The allowance strengthens Silo Pharma's intellectual property position around its lead PTSD candidate, a modest positive for a micro-cap developmental biopharmaceutical name with no approved products. Market impact is limited given the early-stage nature of SPC-15 and the small market capitalization, so the news is unlikely to move broader biotech or equity markets.

biopharmaceutical pharmaceutical intellectual property

Silo Pharma announced that the United States — United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an investigational intranasal therapeutic being developed for post-traumatic stress disorder. The application, titled Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior, covers both composition and method claims for preventing or delaying behavioral responses associated with stress. A Notice of Allowance means the USPTO has completed its examination and determined the application meets patentability requirements, with the patent expected to be granted shortly. The same invention is already covered by a corresponding patent issued by the International — European Patent Office earlier in 2026. CEO Eric Weisblum said securing US patent protection is an important component of the company strategy for SPC-15 as it advances the drug development for PTSD. Silo Pharma is a developmental-stage biopharmaceutical company whose portfolio also includes SP-26 for fibromyalgia and chronic pain, a preclinical Alzheimer's asset, and the wholly owned AI subsidiary QwikAgents. The company holds numerous issued and allowed patents. The stock closed the prior session at 1.72 dollars, down 2.27 percent, and traded lower in pre-market.

stock
Silo Pharma is the central party; the US patent allowance for SPC-15 expands its intellectual property portfolio and supports its development strategy for the PTSD candidate, a modest positive for the micro-cap stock.
Importance 100.0 Sentiment 15.0
govactor
The USPTO issued the Notice of Allowance for the SPC-15 application, the regulatory action that is the core of this event.
Importance 60.0 Sentiment 0.0
per
Silo Pharma CEO Eric Weisblum commented on the strategic importance of the US patent protection for advancing SPC-15 development.
Importance 30.0 Sentiment 0.0
govactor
The International — European Patent Office previously issued a corresponding patent for the same invention, reinforcing the international patent coverage for SPC-15.
Importance 25.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.